Last 48 quarters of trend data · Healthcare · Metabolic & Cardiovascular Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 57.31 | 48.18 | 88.15 | 104.95 | 109.54 | 851.53 | 14.78 | 754.01 | 82.03 | 3355.17 | 5942.39 | 2139.49 | 1236.71 | 1871.86 | 900.67 | 181.49 | 554.20 | 451.55 | 9.47 | 681.34 | 17.23 |
| — | -94.3% | +496.5% | -86.1% | +33.5% | -74.6% | -99.8% | -64.8% | -93.4% | +79.2% | +559.8% | +1078.9% | +123.2% | +314.5% | +9415.7% | -73.4% | +3115.9% | +242.1% | -92.4% | +977.6% | -68.5% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | 54.52 | — | — | — | — | — | — | — | 30.23 | 26.91 | 15.72 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -64.9% | +10.3% | +21.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 95.3% | 91.4% | 87.6% | 83.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -9668.9% | -4982.3% | -21733.9% | -9495.6% | -1621.7% | -3733.3% | -2394.4% | 35.8% | -3901.3% | 21.8% |
| — | -4.7% | -8.6% | -12.4% | -16.1% | 0.0% | 0.0% | +101.0% | +102.0% | +100.5% | +101.1% | -496.2% | -33.5% | -807.7% | -26631.2% | +58.4% | -17251.9% | -202.8% | +103.0% | -921.3% | +106.5% | |
| Operating Margin | -695.4% | -351.3% | -551.1% | -948.7% | -1004.6% | -8613.4% | -167.0% | -9856.3% | -821.4% | -30410.6% | -52277.9% | -15118.0% | -7620.7% | -32345.2% | -14077.2% | -2698.3% | -6491.1% | -4311.8% | -12.2% | -6782.0% | -39.0% |
| — | +95.9% | -230.0% | +90.4% | -22.3% | +71.7% | +99.7% | +34.8% | +89.2% | +6.0% | -271.4% | -460.3% | -17.4% | -650.2% | -115075.1% | +60.2% | -16528.4% | -238.8% | +99.4% | -993.5% | +92.8% | |
| Net Margin | -891.6% | -399.7% | -622.8% | -1064.5% | -1030.9% | -15815.0% | -201.2% | -10220.1% | -886.3% | -34674.9% | -57557.4% | -16244.7% | -8187.6% | -34238.6% | -14837.0% | -2846.1% | -7019.9% | -5658.4% | -22.3% | -7791.4% | -55.0% |
| — | +97.5% | -209.5% | +89.6% | -16.3% | +54.4% | +99.7% | +37.1% | +89.2% | -1.3% | -287.9% | -470.8% | -16.6% | -505.1% | -66500.3% | +63.5% | -12667.7% | -304.3% | +99.0% | -983.1% | +91.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -339.3% | -132.0% | — | — | — | — | — | — | -298.2% | -17.4% | -49.7% | -12.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -420.3% | +88.1% | +4.4% | +62.9% | |
| ROA | -55.5% | -10.1% | -12.4% | -15.3% | -12.8% | -23.0% | -10.8% | -12.1% | -10.6% | -10.8% | -12.3% | -16.6% | -17.5% | -17.0% | -15.4% | -13.8% | -13.1% | -15.4% | -2.4% | -10.5% | -3.7% |
| — | +55.9% | -15.2% | -26.1% | -21.0% | -112.0% | +12.2% | +27.1% | +39.6% | +36.3% | +20.2% | -20.5% | -33.1% | -10.5% | -532.8% | -30.8% | -258.7% | -40.9% | +77.4% | -24.3% | +58.0% | |
| ROIC | -86.6% | -15.8% | -22.5% | -33.0% | -28.1% | -28.9% | -19.3% | -23.1% | -16.2% | -14.7% | -20.6% | -38.3% | -41.0% | -32.9% | -23.9% | -18.7% | -16.0% | -17.0% | -2.5% | -16.1% | -3.9% |
| — | +45.5% | -16.3% | -42.7% | -73.4% | -96.8% | +6.3% | +39.6% | +60.5% | +55.3% | +13.6% | -104.2% | -156.9% | -93.9% | -872.7% | -16.2% | -305.0% | -7.0% | +85.6% | -11.4% | +81.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 7.28 | — | — | — | — | — | — | — | 2.91 | 2.77 | 1.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -80.9% | -17.6% | -9.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.53 | 3.36 | 6.66 | 4.21 | 4.53 | 6.88 | 6.76 | 5.99 | 6.17 | 9.28 | 10.39 | 7.19 | 6.12 | 7.22 | 8.94 | 9.05 | 9.40 | 11.56 | 9.01 | 9.33 | 7.45 |
| — | -51.1% | -1.5% | -29.6% | -26.5% | -25.9% | -34.9% | -16.7% | +0.8% | +28.4% | +16.2% | -20.6% | -34.9% | -37.5% | -0.8% | -3.0% | +26.1% | +88.9% | +52.8% | -22.6% | -51.0% | |
| Quick Ratio | 4.53 | 3.36 | 6.66 | 4.21 | 4.53 | 6.88 | 6.76 | 5.99 | 6.17 | 9.28 | 10.39 | 7.19 | 6.12 | 7.22 | 8.94 | 9.05 | 9.40 | 11.56 | 9.01 | 9.33 | 7.45 |
| — | -51.2% | -1.6% | -29.6% | -26.5% | -25.9% | -34.9% | -16.7% | +0.8% | +28.4% | +16.2% | -20.6% | -34.9% | -37.5% | -0.8% | -3.0% | +26.1% | +88.9% | +52.8% | -22.6% | -51.0% | |
| Interest Coverage | -7.56 | -3.94 | -5.71 | -5.18 | -6.03 | -10.63 | -4.54 | -6.03 | -5.64 | -6.20 | -4.90 | -6.83 | -7.02 | -8.25 | -8.62 | -8.92 | -7.44 | -8.03 | -1.02 | -8.61 | -2.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CYTK stock.
Cytokinetics, Incorporated's current P/E is -9.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cytokinetics, Incorporated's current operating margin is -695.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cytokinetics, Incorporated's business trajectory between earnings reports.